top of page

About Us

The IQ MPS is a collaboration of pharmaceutical and biotechnologies companies created as an Affiliate within the International Consortium for Innovation and Quality in Pharmaceutical Development (also known as the IQ Consortium) to provide a venue for appropriate cross-pharma collaboration and data sharing to facilitate the industry implementation and qualification of MPS models. The IQ Consortium is a leading science-focused, not-for-profit organization with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community (https://iqconsortium.org).

 

The IQ MPS Affiliate is a not-for-profit organization devoted to raising awareness, advancing the science, and supporting the implementation of microphysiological systems in drug discovery. As such, the IQ MPS Affiliate does not collectively endorse microphysiological systems developers or their products. Presentations to the IQ MPS Affiliate are for awareness and information purposes. Individual IQ MPS Affiliate member organizations may engage external organizations as they see fit.
 

MPS 3d Model.png

Leadership

The Steering Committee provides strategic oversight of the initiative's portfolio and is the primary decision-making body for the IQ MPS Affiliate. The Steering Committee has representation from all member companies and acts on the recommendations of working groups and member companies to establish objectives, policies, and plans of action on a consensus basis.

The Executive Committee provides leadership and guidance in the management of the business and affairs of the consortium between meetings of the Steering Committee, implements strategic plans recommended by the Steering Committee, and provides general counsel and tactical advice in support of IQ MPS’s Working Groups.

jason_final.png

Jason Ekert, PhD, MBA

Past Chair (2022-2024)

Head, US Discovery Translational Technology 

UCB

Read More

Rhiannon%2520Hardwick_profile_pic_edited_edited.png

Rhiannon Hardwick, PhD, DABT

Chair (2022-2024)

Scientific Associate Director,

Bristol Myers Squibb

Read More

Anna Kopec_edited.png

Anna Kopec, PhD

Vice Chair (2022-2024)

Senior Principal Scientist, Drug Safety Research & Development,

Pfizer

Read More

Rhiannon David_edited_edited.png

Rhiannon David, PhD

Vice Chair Elect (2023-2024)
Director of MPS, Safety Assessment,

AstraZeneca
Read More

Working Groups

Publish manuscripts outlining organ-specific industry requirements for MPS platforms.

Organotypic Manuscripts

Identify opportunities to engage with health authorities globally on topics related to MPS qualification.

Regulatory
Outreach

Initiate near-term proof of concept study (POC) study for data sharing or prospective collaboration for qualifying MPS system(s) based on specific COUs.

Pilot Project
Teams

Communicate industry perspective and build relationships with key MPS stakeholder to enhance the inclusion of industry priorities.

Strategic Partnerships and Communication

Gap Survey

Conduct and analyze a survey benchmarking how pharmaceutical companies are currently using microphysiological models.

Members

AbbVie, Inc.
Alnylam Pharmaceuticals, Inc.
Amgen, Inc
Astellas Pharma US, Inc.
AstraZeneca
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb Company
Daiichi Sankyo
Eisai, Inc.
Eli Lilly and Company

F. Hoffmann-La Roche

Genentech, Inc.

GSK
I
ncyte
Janssen Pharmaceuticals, Inc.
Merck & Co., Inc.
Merck Healthcare KGaA
Novartis Pharmaceuticals Corporation

Novo Nordisk
Pfizer

Sanofi

Servier
Takeda
Vertex Pharmaceuticals Incorporated

UCB

bottom of page